Cancer Genetics, Inc. Announces Appointment of Venkatadri Bobba to Cancer Genetics India's Board of Directors
16 December 2014 - 11:30PM
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"), an
emerging leader in DNA-based cancer diagnostics, announced today
the addition of Venkatadri Bobba to Cancer Genetics India's Board
of Directors.
"Mr Bobba has a tremendous track record of leadership in the
life sciences. His experiences and insights will bring significant
value to CG India's board of directors," said Panna Sharma, CEO and
President of Cancer Genetics, Inc.
Bobba brings with him more than 36 years of corporate leadership
experience in the pharmaceutical and life sciences
industries. Bobba, who is currently a General Partner with
Ventureast, has held executive leadership positions at a number of
life sciences companies in the US, EU, and Asia. Prior to
joining Ventureast, Bobba served as Senior Vice President of
Operations at Aradigm Corporation and from 2001-2003 was
Executive Vice President at Diosynth, a division of Akzo
Nobel. From 1995 to 2000, Bobba served as President and
CEO at Molecular Biosystems, an NYSE listed company. Previous to
that, Bobba was Executive Vice President of Centocor Inc
(now Jansen Biotech, a division of Johnson & Johnson)
and held several executive positions, including President, at
Warner-Lambert, Indonesia. He also previously served as V.P. of
Manufacturing at Parke-Davis, USA (now part of
Pfizer).
"It is an exciting time to be part of such a high-growth market
like India. I look forward to the growth and much
needed innovation that CG India will bring to Indian cancer
patients and hospitals at an affordable price," said Bobba. "CG
India has established itself as a leader in the oncology
diagnostics market with a firm commitment to innovation. I
look forward to helping the company offer novel cancer diagnostic
tests to all patients who need them to improve their clinical
outcomes."
Bobba is an active board member of three US-based companies,
including Diabetomics Inc., Melior Pharma, and Sparsha Inc.
Bobba also sits on the board of several Indian-based companies,
including Portea, Richcore, and Sparsha Pharma, an Indian
subsidiary of Napo Pharmaceuticals. Additionally, he serves on the
advisory board for the SOHO Group, the largest pharmaceutical
company in Indonesia, and for Cumberland Pharmaceuticals, Inc.,
USA, a Nasdaq listed company.
A pharmacist by training, Bobba graduated with gold medal honors
from Andhra University and holds an MBA from Farleigh Dickinson
University, New Jersey.
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
labs are focused entirely on maintaining clinical excellence and
are both CLIA certified and CAP accredited and have licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements pertaining
to future financial and/or operating results, future growth in
research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. products and services,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to, statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or discontinuance of trials,
risks that the transaction will not close or, if it closes, will
not realize the currently anticipated benefits, uncertainty in the
results of clinical trials or regulatory approvals, need and
ability to obtain future capital, maintenance of intellectual
property rights and other risks discussed in the Company's Form
10-K for the year ended December 31, 2013 and 10-Q for the quarter
ended September 30, 2014 along with other filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Cancer Genetics
disclaims any obligation to update these forward-looking
statements.
CONTACT: Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com
Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2024 to May 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From May 2023 to May 2024